Skip to main content
Evidence Based Longevity (EBL)Check what I take
Evidence Trace, complete trial record
In plain terms

In plain terms: Beta-Alanine has some human trial evidence supporting it, but the evidence is not yet strong enough for EBL to call it established. It is worth knowing about and worth discussing with your clinician.

Beta-Alanine

B Supported: a good trial, backed by more
Category Supplements
Evidence Meta-analysis of RCTs
Reviewed July 2026
PMIDs 27797728 · 22270875
The endpoint this grade is based on: Objectively measured functional outcome, High intensity exercise capacity, especially efforts of 1 to 4 minutes; a performance surrogate, not a clinical outcome

The evidence as the record states it

Evidence record
PMID 27797728 PMID 22270875

Saunders et al. (British Journal of Sports Medicine, 2017; PMID 27797728) and Hobson et al. (2012 meta-analysis; PMID 22270875): meta-analyses: beta-alanine improved high-intensity exercise capacity, especially for efforts of 1 to 4 minutes. Grade B: robust meta-analytic evidence on a performance surrogate.

PMID 27797728 PMID 22270875

Why Grade B and not Grade A

Grade B reflects moderate human evidence -- typically a single strong trial, multiple smaller trials, or surrogate endpoint data without hard clinical outcome replication. To reach Grade A, Beta-Alanine would require at least one additional independent randomized trial demonstrating a hard clinical endpoint or objectively measured functional outcome in a comparable population.

What would move this grade

An independent randomized trial demonstrating a hard clinical endpoint -- mortality, major adverse event, or objectively confirmed functional improvement -- in an adequately powered sample, with results independently replicated, would support Grade A.

How this was studied

Form: Oral beta-alanine taken daily (chronic ingestion), compared with placebo in double-blind trials (Saunders 2017, PMID 27797728). Delivery format per trial is not tabulated; one included trial used a slow-release formulation (Hobson 2012, PMID 22270875). · Dose: 2.4 to 6.4 g per day, often loaded upward or stepped down, for total intakes of about 109 to 448 g; median total 179 g (Hobson 2012, PMID 22270875). Total amount ingested did not moderate the effect (Saunders 2017, PMID 27797728). · Population: Healthy participants only: 40 studies, 1,461 participants (Saunders 2017, PMID 27797728). 15 studies, 360 participants, mostly recreationally active or trained young men, with three groups of women and one group of older men and women (Hobson 2012, PMID 22270875). · Duration: 21 to 90 days, roughly 3 to 13 weeks (Hobson 2012, PMID 22270875). Duration range in the larger meta-analysis is not stated in its abstract (Saunders 2017, PMID 27797728).

How to track whether this is working Performance on time-to-exhaustion or high-intensity interval output (e.g., Wingate test, repeated sprint) at baseline and 4 weeks. Tingling (paresthesia): this is a benign but common side effect that reduces with sustained-release formulations or split dosing. The ergogenic effect is specific to exercise lasting 1-4 minutes at high intensity; do not expect benefit for strength or endurance activities outside this range.